34 0.13 (0.38%) | 01-17 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 40 | 1-year : | 46.72 |
Resists | First : | 34.25 | Second : | 40 |
Pivot price | 31 | |||
Supports | First : | 29.49 | Second : | 26.54 |
MAs | MA(5) : | 32.62 | MA(20) : | 30.27 |
MA(100) : | 24.74 | MA(250) : | 18.84 | |
MACD | MACD : | 1.2 | Signal : | 0.8 |
%K %D | K(14,3) : | 95.1 | D(3) : | 90.3 |
RSI | RSI(14): 69.2 | |||
52-week | High : | 34.25 | Low : | 9.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ELMD ] has closed below upper band by 1.1%. Bollinger Bands are 45.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 34.27 - 34.37 | 34.37 - 34.49 |
Low: | 32.86 - 32.99 | 32.99 - 33.12 |
Close: | 33.78 - 33.97 | 33.97 - 34.18 |
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Wed, 15 Jan 2025
Electromed stock soars to all-time high of $31.98 By Investing.com - Investing.com Nigeria
Thu, 09 Jan 2025
Electromed (NYSE:ELMD) Downgraded to Buy Rating by StockNews.com - MarketBeat
Sat, 14 Dec 2024
(ELMD) Trading Advice - Stock Traders Daily
Wed, 27 Nov 2024
Undiscovered Gems in the US Stock Market for November 2024 - Simply Wall St
Sat, 16 Nov 2024
Electromed, Inc. (AMEX:ELMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Wed, 13 Nov 2024
Electromed Inc (ELMD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
AMEX
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 9 (M) |
Shares Float | 6 (M) |
Held by Insiders | 26.8 (%) |
Held by Institutions | 34.1 (%) |
Shares Short | 35 (K) |
Shares Short P.Month | 32 (K) |
EPS | 0.57 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 5.15 |
Profit Margin | 9.4 % |
Operating Margin | 15.7 % |
Return on Assets (ttm) | 8.3 % |
Return on Equity (ttm) | 12.5 % |
Qtrly Rev. Growth | 9 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 6.33 |
EBITDA (p.s.) | 0.85 |
Qtrly Earnings Growth | 80.9 % |
Operating Cash Flow | 9 (M) |
Levered Free Cash Flow | 8 (M) |
PE Ratio | 58.62 |
PEG Ratio | 1.8 |
Price to Book value | 6.58 |
Price to Sales | 5.36 |
Price to Cash Flow | 32.38 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |